AU2009302375B2 - 1-phenylpyrrole compounds - Google Patents

1-phenylpyrrole compounds Download PDF

Info

Publication number
AU2009302375B2
AU2009302375B2 AU2009302375A AU2009302375A AU2009302375B2 AU 2009302375 B2 AU2009302375 B2 AU 2009302375B2 AU 2009302375 A AU2009302375 A AU 2009302375A AU 2009302375 A AU2009302375 A AU 2009302375A AU 2009302375 B2 AU2009302375 B2 AU 2009302375B2
Authority
AU
Australia
Prior art keywords
phenyl
methyl
pyrrole
carboxamide
methylsulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2009302375A
Other languages
English (en)
Other versions
AU2009302375A1 (en
Inventor
Kazumasa Aoki
Yusuke Asoh
Tsuyoshi Homma
Masatoshi Honzumi
Richard Martin
Raju Mohan
John Nuss
Keiji Saito
Hiroyuki Tsuruoka
Tie-Lin Wang
Matthew Williams
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Exelixis Inc
Original Assignee
Exelixis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Exelixis Inc filed Critical Exelixis Inc
Publication of AU2009302375A1 publication Critical patent/AU2009302375A1/en
Application granted granted Critical
Publication of AU2009302375B2 publication Critical patent/AU2009302375B2/en
Assigned to EXELIXIS, INC. reassignment EXELIXIS, INC. Request for Assignment Assignors: DAIICHI SANKYO COMPANY, LIMITED, EXELIXIS, INC.
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/42—Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22—Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
AU2009302375A 2008-10-08 2009-10-07 1-phenylpyrrole compounds Ceased AU2009302375B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10380408P 2008-10-08 2008-10-08
US61/103,804 2008-10-08
PCT/US2009/059852 WO2010042626A1 (en) 2008-10-08 2009-10-07 1-phenylpyrrole compounds

Publications (2)

Publication Number Publication Date
AU2009302375A1 AU2009302375A1 (en) 2010-04-15
AU2009302375B2 true AU2009302375B2 (en) 2015-03-26

Family

ID=41328965

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009302375A Ceased AU2009302375B2 (en) 2008-10-08 2009-10-07 1-phenylpyrrole compounds

Country Status (12)

Country Link
US (1) US8642640B2 (enExample)
EP (1) EP2349996B1 (enExample)
JP (2) JP5767587B2 (enExample)
KR (1) KR101671868B1 (enExample)
CN (1) CN102177137B (enExample)
AU (1) AU2009302375B2 (enExample)
BR (1) BRPI0920551B1 (enExample)
CA (1) CA2736930C (enExample)
ES (1) ES2453500T3 (enExample)
IL (1) IL212171A (enExample)
TW (2) TWI460161B (enExample)
WO (1) WO2010042626A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102177137B (zh) * 2008-10-08 2015-03-18 埃克塞利希斯股份有限公司 1-苯基吡咯化合物
CN104478782B (zh) * 2015-01-13 2016-03-16 佛山市赛维斯医药科技有限公司 一类含烷氧苯基和二烯氟代金刚烷结构的化合物和用途
CN104447484B (zh) * 2015-01-13 2016-06-08 佛山市赛维斯医药科技有限公司 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
CN104447485A (zh) * 2015-01-13 2015-03-25 佛山市赛维斯医药科技有限公司 一种含腈基苯和二烯金刚烷结构的化合物、其制备方法和用途
CN104478781A (zh) * 2015-01-13 2015-04-01 佛山市赛维斯医药科技有限公司 二烯金刚烷类化合物、其制备方法和用途
AU2020371836B2 (en) 2019-10-25 2026-01-29 Sunshine Lake Pharma Co., Ltd. Pyrrole amide compound and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012642A2 (en) * 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI444185B (zh) 2007-04-09 2014-07-11 Daiichi Sankyo Co Ltd 吡咯衍生物之阻轉異構物
CN102177137B (zh) * 2008-10-08 2015-03-18 埃克塞利希斯股份有限公司 1-苯基吡咯化合物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006012642A2 (en) * 2004-07-30 2006-02-02 Exelixis, Inc. Pyrrole derivatives as pharmaceutical agents

Also Published As

Publication number Publication date
CN102177137B (zh) 2015-03-18
JP5767587B2 (ja) 2015-08-19
HK1155162A1 (en) 2012-05-11
IL212171A0 (en) 2011-06-30
CN102177137A (zh) 2011-09-07
CA2736930A1 (en) 2010-04-15
TWI532717B (zh) 2016-05-11
EP2349996A1 (en) 2011-08-03
BRPI0920551B1 (pt) 2021-12-14
CA2736930C (en) 2016-11-22
JP2014196366A (ja) 2014-10-16
JP2012505226A (ja) 2012-03-01
TWI460161B (zh) 2014-11-11
TW201028376A (en) 2010-08-01
TW201514144A (zh) 2015-04-16
JP5837655B2 (ja) 2015-12-24
US8642640B2 (en) 2014-02-04
US20110263544A1 (en) 2011-10-27
AU2009302375A1 (en) 2010-04-15
WO2010042626A1 (en) 2010-04-15
KR20110091664A (ko) 2011-08-12
ES2453500T3 (es) 2014-04-08
BRPI0920551A2 (pt) 2020-08-11
EP2349996B1 (en) 2014-01-01
KR101671868B1 (ko) 2016-11-03
IL212171A (en) 2015-11-30

Similar Documents

Publication Publication Date Title
RU2470916C2 (ru) Производные пиррола как лекарственные вещества
CA2647677C (en) Cyclohexylpyrazole-lactam derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
JP5363312B2 (ja) ピロール誘導体のアトロプ異性体
JP5837655B2 (ja) １−フェニルピロール化合物
JP6121952B2 (ja) （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体
SK286471B6 (sk) Deriváty 2-fenylpyran-4-ónu, spôsob ich prípravy,farmaceutické kompozície s ich obsahom a ich použitie
HK1155162B (en) 1-phenylpyrrole compounds
JP2004526752A (ja) Δ１−ピロリン類の製造方法
HK1155163B (en) Atropisomers of (hydroxyalkyl) pyrrole derivatives
WO2010113952A1 (ja) ムスカリン受容体拮抗薬

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: EXELIXIS, INC.

Free format text: FORMER OWNER(S): EXELIXIS, INC.; DAIICHI SANKYO COMPANY, LIMITED

MK14 Patent ceased section 143(a) (annual fees not paid) or expired